Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-06-28
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotechnology company using proprietary data, automated labs, and AI software to discover drugs and run pharma collaborations.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof Drives the Next Rerating
The upside is real if platform validation broadens from one encouraging rare-disease signal into a repeatable asset engine. Until then, the stock is likely to trade as cash, optionality, and a few high-stakes milestones.

Analysis

Thesis
Recursion is a clinical-proof rerating story: if its proprietary data, automated labs, and AI workflow convert multiple internal and partnered programs into repeatable human validation by 2031, the market can shift from valuing cash and option value to valuing a scalable asset engine with recurring platform-like economics.
Last Economy Alignment
Cheaper cognition helps Recursion because models sit inside proprietary data and lab loops, but value still depends on clinical proof and regulator acceptance.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.0x (from 5 most recent analyses)
Reasoning
This is a proof-and-mix rerating case, not a simple volume case. If one lead owned asset gets a credible late-stage path, a second internal program validates the engine, and partner revenue becomes more recurring, investors can value the business as a repeatable drug-creation system rather than a cash-backed AI concept. That supports meaningful upside, but not a full software-style multiple.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is validation, not imagination. Recursion already has the data, automation, and AI stack; what it still must prove is that these assets repeatedly create clinically relevant outcomes fast enough to improve partner economics and outrun dilution. The decisive gates are REC-4881 regulatory clarity, follow-on human data from REC-1245 and other internal assets, continued burn discipline, and credible remediation of control weaknesses.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.43
It owns the hard-to-copy part of AI drug discovery: the machines, data, and workflow that turn ideas into real biological tests. But if those tests do not keep turning into drugs that work in people, the market will treat the whole stack as an expensive lab rather than a compounding platform.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$6.64
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case